...
首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >Synthesis of 7,9-diazabicyclo(4.2.2)decanes as conformationally restricted kappa receptor agonists: fine tuning of the dihedral angle of the ethylenediamine pharmacophore.
【24h】

Synthesis of 7,9-diazabicyclo(4.2.2)decanes as conformationally restricted kappa receptor agonists: fine tuning of the dihedral angle of the ethylenediamine pharmacophore.

机译:合成7,9-二氮杂双环(4.2.2)癸烷作为构象受限的κ受体激动剂:乙二胺药效基团的二面角的微调。

获取原文
获取原文并翻译 | 示例
           

摘要

In order to slightly modify the orientation of the pharmacophoric structural elements of the potent kappa agonists 7 and 8, the three-membered bridge of these compounds was enlarged to four carbon atoms. Reductive amination of the bicyclic ketone 11 with pyrrolidine and NaBH(OAc)3 provided the pyrrolidine 12 with excellent diastereoselectivity (>99:1). The diastereomeric pyrrolidine 24 was established by a stepwise strategy, involving an unselective nucleophilic substitution of the triflate 20 with NaN3 as key step. The synthesis of 9 and 10 was completed by LiAlH4 reduction, replacement of the PMB group at N-9 with a (3,4-dichlorophenyl)acetyl residue and the N-7-benzyl group with the methoxycarbonyl moiety. The kappa receptor affinity of the new compounds is strongly dependent on the stereochemistry and the N-7-substituent. The (1RS,2SR,6SR)-configured pyrrolidine 9 with a methoxycarbonyl moiety at N-7 represents the most potent kappa ligand (Ki=65 nM) of this series. The 65fold lower kappa affinity of 9 compared with its smaller homologue 7 is partly explained by 9 being a racemic mixture, and the slightly modified dihedral angle of the pharmacophoric N(pyrrolidine)-C-C-N(dichlorophenylacetyl) substructure. However, the additional methylene moiety, which enlarges the size of the bridge, is assumed to be responsible for the reduced kappa affinity.
机译:为了稍微改变有效κ激动剂7和8的药效团结构元件的取向,将这些化合物的三元桥扩大到四个碳原子。用吡咯烷和NaBH(OAc)3对双环酮11进行还原胺化,使吡咯烷12具有优异的非对映选择性(> 99:1)。非对映体吡咯烷24是通过逐步策略建立的,涉及用NaN 3作为关键步骤的三氟甲磺酸酯20的非选择性亲核取代。 9和10的合成通过LiAlH4还原,在N-9处的PMB基团被(3,4-二氯苯基)乙酰基残基和具有甲氧基羰基部分的N-7-苄基基团完成。新化合物的κ受体亲和力在很大程度上取决于立体化学和N-7取代基。 (1RS,2SR,6SR)构成的吡咯烷9在N-7处具有甲氧基羰基部分,代表该系列中最有效的Kappa配体(Ki = 65 nM)。 9与其较小的同系物7相比,其kappa亲和力降低了65倍,部分原因是9是外消旋混合物,药效基团N(吡咯烷)-C-C-N(二氯苯基乙酰基)亚结构的二面角略有改变。然而,假定额外的亚甲基部分会增加桥的大小,这是造成κ亲和力降低的原因。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号